- Home
- TACT vs IGC Comparison
TACT vs IGC Comparison
Compare TACT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- IGC
- Stock Information
- Founded
- TACT 1996
- IGC 2005
- Country
- TACT United States
- IGC United States
- Employees
- TACT N/A
- IGC N/A
- Industry
- TACT Computer peripheral equipment
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- IGC Health Care
- Exchange
- TACT Nasdaq
- IGC Nasdaq
- Market Cap
- TACT 42.2M
- IGC 39.8M
- IPO Year
- TACT 1996
- IGC N/A
- Fundamental
- Price
- TACT $4.63
- IGC $0.43
- Analyst Decision
- TACT Strong Buy
- IGC Strong Buy
- Analyst Count
- TACT 1
- IGC 2
- Target Price
- TACT $5.00
- IGC $4.00
- AVG Volume (30 Days)
- TACT 68.6K
- IGC 1.4M
- Earning Date
- TACT 11-06-2025
- IGC 11-11-2025
- Dividend Yield
- TACT N/A
- IGC N/A
- EPS Growth
- TACT N/A
- IGC N/A
- EPS
- TACT N/A
- IGC N/A
- Revenue
- TACT $47,949,000.00
- IGC $1,327,000.00
- Revenue This Year
- TACT $21.67
- IGC $15.26
- Revenue Next Year
- TACT $7.63
- IGC $3.41
- P/E Ratio
- TACT N/A
- IGC N/A
- Revenue Growth
- TACT N/A
- IGC 24.95
- 52 Week Low
- TACT $3.12
- IGC $0.25
- 52 Week High
- TACT $4.89
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- TACT 64.75
- IGC 58.95
- Support Level
- TACT $4.09
- IGC $0.38
- Resistance Level
- TACT $4.76
- IGC $0.47
- Average True Range (ATR)
- TACT 0.18
- IGC 0.04
- MACD
- TACT -0.00
- IGC -0.00
- Stochastic Oscillator
- TACT 80.64
- IGC 44.42
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.